Reconstitution of Nucleosome Demethylation and Catalytic Properties of a Jumonji Histone Demethylase

Graduate Program in Chemistry and Chemical Biology, University of California, San Francisco, San Francisco, CA 94158, USA.
Chemistry & biology (Impact Factor: 6.65). 04/2013; 20(4):494-9. DOI: 10.1016/j.chembiol.2013.03.008
Source: PubMed


Jumonji histone demethylases catalyze removal of methyl marks from lysine residues in histone proteins within nucleosomes. Here, we show that the catalytic domain of demethylase JMJD2A (cJMJD2A) utilizes a distributive mechanism to remove the histone H3 lysine 9 trimethyl mark. By developing a method to assess demethylation of homogeneous, site-specifically methylated nucleosomes, we determined that the kinetic parameters for demethylation of nucleosomes by cJMJD2A are comparable to those of peptide substrates. These findings imply that other domains of the demethylase or its protein partners may contribute to nucleosome recognition in vivo and, in this way, may further regulate demethylation activity and processivity. The quantitative assays of nucleosome demethylation developed in our work provide a platform for future work with complex chromatin substrates and full-length demethylases.

1 Follower
10 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Post-translational histone methylation is a dynamic and reversible process that is in-volved in the spatio-temporal regulation of gene transcription and contributes to various cellular phenotypes. Methylation of histone H3 at lysine 9 (H3K9), which is generally a transcriptional repression mark, is demethylated by H3K9 specific demethylases, leading to transcriptional activation. However, how multiple demethylases with the same substrate specificity differ in their chromatin targeting mechanisms has not been well un-derstood. Unlike other H3K9-specific deme-thylases, it has been reported that JMJD1A likely forms a homodimer, but a detailed mode of dimerization and the possible link between structure and enzymatic activity have remained unresolved. Here, we report the structure-function relationship of JMJD1A in detail. First, JMJD1A forms a homodimer through its catalytic domains, bringing the two active sites close together. Second, increasing the concentration of JMJD1A facilitates efficient production of unmethylated product from dimethyl-H3K9 and decreases the release of the monomethylated intermediate. Finally, substituting one of the two active sites with an inactive mutant results in a significant reduction of the demethylation rate without changing the affinity to the intermediate. Given this evidence, we propose a substrate channeling model for the efficient conversion of dimethylated H3K9 into the unmethylated state. Our study provides valuable information that will help in understanding the redundancy of H3K9-specific demethylases and the com-plementary activity of their unique structures and enzymatic properties for appropriate control of chromatin modification patterns.
    Journal of Biological Chemistry 11/2013; 288(52). DOI:10.1074/jbc.M113.492595 · 4.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since the identification of the Jumonji C-domain-containing α-ketoglutarate-dependent histone Nε-methyl-lysine demethylases in 2006, exemplified with the JMJD2 (Jumonji domain-containing protein 2) and JARID1 (Jumonji, AT rich interactive domain 1) families of the Nε-trimethyl-lysine demethylases, there has been a steady increase in our functional understanding of these two families of the non-heme hydroxylase enzymes which achieve Nε-methyl-lysine demethylation via the prior Nε-CH3 C-hydroxylation. These enzymatic demethylation reactions have been shown to constitute critical epigenetic regulatory mechanisms and have been proposed as novel cancer therapeutic targets. Therefore, we have also seen medicinal chemistry efforts during the past few years toward identifying potent and selective inhibitors for the demethylation reactions catalyzed by the JMJD2 and JARID1 proteins. In the meantime, biochemical and structure-based mechanistic investigations have also furnished molecular insights of the catalysis and substrate recognition for these demethylation reactions. An account on the current knowledge of the chemistry and biology of the demethylation reactions catalyzed by the JMJD2 and JARID1 families of demethylases will be presented in this review. It is hoped that this article will also be able to set a stage for future research at the interface of chemistry and biology on the demethylation reactions catalyzed by these fascinating enzymes.
    Medicinal Chemistry Communication 02/2014; 5(3). DOI:10.1039/C3MD00325F · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Posttranslational modifications (PTMs) of chromatin are involved in gene regulation, thereby contributing to cell differentiation, lineage determination, and organism development. Discrete chromatin states are established by the action of a large set of enzymes that catalyze the deposition, propagation, and removal of histone PTMs, thereby modulating gene expression. Given their central role in determining and maintaining cellular phenotype, as well as in controlling chromatin processes such as DNA repair, the dysregulation of these enzymes can have serious consequences, and can result in cancer and neurodegenerative diseases. Thus, such chromatin regulator proteins are promising drug targets. However, they are often present in large, modular protein complexes that specifically recognize target chromatin regions and exhibit intricate regulation through preexisting histone marks. This renders the study of their enzymatic mechanisms complex. Recent developments in the chemical production of defined chromatin substrates show great promise for improving our understanding of the activity of chromatin regulator complexes at the molecular level. Herein I discuss examples highlighting the application of synthetic chromatin to study the enzymatic mechanisms and regulatory pathways of these crucial protein complexes in detail, with potential implications for assay development in pharmacological research.
    ChemMedChem 03/2014; 9(3). DOI:10.1002/cmdc.201300487 · 2.97 Impact Factor
Show more


10 Reads
Available from